Chronic obstructive pulmonary disease (COPD) is a group of conditions that cause breathing problems. The two main ones are chronic bronchitis and emphysema. Researchers have identified alpha-1 ...

Alpha-1 antitrypsin (AAT) deficiency is a genetic disease where your body doesn’t make enough normal functioning AAT. AAT is a protein your liver makes. AAT has many important roles in your body, ...

Prime Medicine announces promising preclinical results for a novel AATD treatment using advanced Prime Editing technology, aiming for clinical trials by mid-2026. Prime Medicine, Inc. announced the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Arrowhead Pharmaceuticals announced that the first ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients with alpha-1 antitrypsin deficiency (AATD) ...

Emphysema is a type of chronic obstructive pulmonary disease (COPD) that affects approximately 3 million people in the United States. While smoking is considered the most common cause, some people may ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the advancement of its investigational program targeting alpha-1 antitrypsin deficiency (AATD), a rare, ...

Patients with lung disease are more likely to develop heart disease independent of any risk factors, according to new research. Boosting levels of a deficient protein has clear survival benefits for ...

BEAM-302 demonstrated safety and efficacy in increasing AAT levels and reducing mutant protein in alpha-1 antitrypsin deficiency patients. Beam Therapeutics announced promising initial results from ...

Researchers at Saint Louis University's School of Medicine, in collaboration with Arrowhead Pharmaceuticals and Takeda Pharmaceuticals, report the first effective drug to treat a rare, genetic liver ...